Document is current
Any future updates will be listed below
-
Authors
Garretson, Tyler A.
Liu, Jiaojiao
Li, Shuk Hang https://orcid.org/0000-0001-8462-6657
Scher, Gabrielle https://orcid.org/0000-0002-7571-4791
Santos, Jefferson J. S. https://orcid.org/0000-0001-5895-4163
Hogan, Glenn
Vieira, Marcos Costa
Furey, Colleen
Atkinson, Reilly K.
Ye, Naiqing https://orcid.org/0009-0003-6232-8570
Ort, Jordan T. https://orcid.org/0000-0001-6977-4168
Kim, Kangchon
Hernandez, Kevin A.
Eilola, Theresa
Schultz, David C. https://orcid.org/0000-0002-7890-8815
Cherry, Sara https://orcid.org/0000-0003-3956-6610
Cobey, Sarah https://orcid.org/0000-0001-5298-8979
Hensley, Scott E. https://orcid.org/0000-0002-2928-7506
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (75N93021C00015, R01AI08686, 75N93021C00015, 75N93021C00015)
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 20 February 2025
First Online: 13 March 2025
Competing interests
: S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. S.E.H. reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax and Merck. T.A.G. was an employee of the University of Pennsylvania when the work was completed and is now an employee of GSK. The authors declare no other competing interests.
